Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00215397 · ClinicalTrials.gov registry record · Phase 2

Study in Patients With Asthma

A Phase 2 study of Asthma, sponsored by Dey.

Completed
Registry status
Phase 2
Development phase
16
Enrollment target
3
Study locations

NCT00215397: Completed Phase 2 study of Asthma, sponsored by Dey.

NCT00215397 is a Phase 2 study of Asthma that has completed, run by Dey. The registered enrollment target is 16 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00215397, a Phase 2 study of Asthma, has completed, sponsored by Dey.

COMPLETED
Registry status
Phase 2
Development phase
16 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this study is to determine which dose of the investigational drug is the most safe and effective in the treatment of asthma compared to the control drug.

Conditions Studied

Interventions

  • DRUG Formoterol Fumarate

Study Locations (3)

California

  • Research Site - Long Beach

Colorado

  • Research Site - Denver

Oregon

  • Research Site - Medford

Trial Details

FieldValue
Enrollment Target 16 participants
Est. Completion 2005-12
Phase Phase 2
Dey

21 total trials

What the finished NCT00215397 record still lists

NCT00215397 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 1 intervention - of which Formoterol Fumarate is the first listed.

NCT00215397 reports a single indexed study location in California, Colorado, Oregon.

Frequently Asked Questions

What is clinical trial NCT00215397 about?

NCT00215397 is a clinical study titled "Study in Patients With Asthma". The purpose of this study is to determine which dose of the investigational drug is the most safe and effective in the treatment of asthma compared to the control drug.

What is the current status of trial NCT00215397?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. Estimated completion is 2005-12.

What conditions does trial NCT00215397 study?

This clinical trial studies the following conditions: Asthma.

What interventions are being tested in trial NCT00215397?

The interventions under investigation include: Formoterol Fumarate (DRUG).

Who is sponsoring clinical trial NCT00215397?

This trial is sponsored by Dey, which has 21 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00215397 being conducted?

This trial has 3 study locations across California, Colorado, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00215397's enrollment target sits among peer trials

16 350th of 374 higher than 22 of 374 other Asthma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02422641 · 16 participants · Phase 2

    Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

  • NCT02851758 · 16 participants · NA

    Transplantation of Autologously Derived Mitochondria Following Ischemia

  • NCT03291028 · 16 participants

    Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

  • NCT03425526 · 16 participants · Phase 1

    Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease

Source: ClinicalTrials.gov NCT00215397, the US trial registry maintained by the National Library of Medicine. NCT00215397 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.